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ABSTRACT
Colorectal cancer (CRC) is a leading cause of death worldwide. Surgical 
intervention is a successful treatment for stage I patients, whereas other more 
advanced cases may require adjuvant chemotherapy. The selection of effective 
adjuvant treatments remains, however, challenging. Accurate patient stratification 
is necessary for the identification of the subset of patients likely responding to 
treatment, while sparing others from pernicious treatment. Targeted sequencing 
approaches may help in this regard, enabling rapid genetic investigation, and at the 
same time easily applicable in routine diagnosis. 
We propose a set of guidelines for the identification, including variant calling 
and filtering, of somatic mutations driving tumorigenesis in the absence of matched 
healthy tissue. We also discuss the inclusion criteria for the generation of our gene 
panel. Furthermore, we evaluate the prognostic impact of individual genes, using 
Cox regression models in the context of overall survival and disease-free survival. 
These analyses confirmed the role of commonly used biomarkers, and shed light on 
controversial genes such as CYP2C8. 
Applying those guidelines, we created a novel gene panel to investigate the onset 
and progression of CRC in 273 patients. Our comprehensive biomarker set includes 
266 genes that may play a role in the progression through the different stages of 
the disease. Tracing the developmental state of the tumour, and its resistances, is 
instrumental in patient stratification and reliable decision making in precision clinical 
practice.
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INTRODUCTION
Colorectal cancer overview
Colorectal cancer (CRC) is one of the most common 
malignancies in the World; nearly 1.4 million new cases 
are diagnosed every year (WHO Globocan 2012). CRC 
is particularly prevalent in developed countries. For 
example, more than 5,000 new cases were recorded in 
2014 in Denmark (Danish Colon Cancer Group, Annual 
Report 2014) with approximately two out of three being 
colon cancers (CC). Metastatic disease, synchronous or 
metachronous, will typically be detected in half of the 
patients. An overall 5-year survival of 60% underlines the 
need for improved treatment. 
Surgery is the cornerstone in the treatment of 
patients with CRC and can be performed with curative 
intent in patients with stage I disease, which is restricted 
to the inner part of the bowel wall. At the other end of 
the spectrum, patients with metastatic disease, stage IV, 
are primarily treated with palliative chemotherapy and 
only a small fraction of them become long term survivors. 
The remaining patients, i.e. stage II disease growing to 
the outer layers of or through the bowel wall, and stage 
III involving regional lymph nodes, constitute a special 
clinical challenge. The majority is cured by surgery and an 
additional small fraction responds favourably to adjuvant 
chemotherapy. The challenge is to identify those patients 
who will benefit from adjuvant treatment and spare those 
who will not from toxic, unnecessary treatment. Therefore, 
new biomarkers to improve selection for adjuvant therapy 
are needed. 
Advances in precision medicine 
The list of genes in which some mutations confer 
resistance to specific treatments has grown over the recent 
years and currently includes many examples. De Roock 
et al. [1] evaluated the role of KRAS, BRAF, PIK3CA and 
PTEN mutations in CRC and the efficacy of anti-EGFR 
therapy. Similarly, Modest et al. [2] investigated KRAS 
p.12 mutated CRCs. Dienstmann et al. [3] evaluated 
the improvement on the prediction of overall survival in 
the presence of microsatellite instability and considered 
BRAF V600E and KRAS mutations in a cohort of non-
metastatic stage II and stage III CC patients. Keum et al. 
[4] proposed a panel for the stratification of CRC patients 
consisting on mutations in KRAS, BRAF and PIK3CA and 
the expression of IRS1, IRS2, FASN, and CTNNB1 as these 
genes are implicated in the insulin signaling pathway. 
The American Society for Clinical Pathology, College 
of American Pathologists, Association for Molecular 
Pathology and American Society of Clinical Oncology 
have recently promulgated a series of guidelines for the 
evaluation of CRC [5]. The collection of biomarkers 
suggested in these Good Practice Guidelines includes: 
KRAS and NRAS codons 12 and 13 of exon 2, 59 and 61 
of exon 3, 117 and 146 of exon 4; BRAF pV600, genes 
related to DNA mismatch repair status testing.
A steadily growing battery of precision medicine 
approaches based on mutations in these genes has 
increased the treatment possibilities for CRC patients 
over the last decade. These innovative therapies may be 
administered alone or as part of a combination protocol 
including also traditional therapeutic approaches. 
Additional targeted approaches attempt at bypassing 
the resistance to other treatments. This is the case of the 
resistance to EGFR-targeted therapies, developed by 
carriers of mutations in RAS proto-oncogenes [2].
All developments in the field led to current treatment 
of CRC being customised to the genome of the patient’s 
individual tumour by necessity. Tran and collaborators 
neatly reviewed the treatment alternatives for some of the 
aforementioned mutations [6]. 
Summary of the work presented in this 
manuscript
We propose a novel panel of 266 genes that 
may be involved in onset and progression of CRC. 
Our panel is much more comprehensive than existing 
similar gene collections. and has been designed to 
include genes that are likely to play a causative role 
in the progression through the different developmental 
stages of the malignancy. Consequently, our panel may 
be instrumental in the decision making for precision 
clinical practice. We detail the steps taken for the 
selection of genes for our biomarker panel. First, we 
propose guidelines for the thorough filtering of germline 
variants in a setting, where matched healthy tissue 
is not available. This has a dual purpose: to reduce 
the analytical and computational requirements of the 
annotation of variants, facilitating an alignment with 
the throughput demands of a clinical setting, but also 
to ensure patient anonymity, a common requirement 
in precision medicine. Second, we propose guidelines 
for the inclusion of genes in a biomarker panel. Our 
integrative approach combines information from the 
automatic mining of the biomedical literature, different 
state-of-the-art databases (dbSNP, COSMIC, Uniprot, 
among others), and the largest cancer genomics effort to 
date [7]. The biomarker panel is also complemented with 
common targets for therapeutic drugs and genes deemed 
significant from our expertise on systems biology 
approaches. Third, we use Cox regression models to 
determine the role of specific genes in the survival of 
patients. This approach confirms the role of oncogenes 
recurrently involved in the onset and progression of CRC 
and contributes to the controversial role of CYP2C8 as 
an active driver of cancer. 
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RESULTS AND DISCUSSION
NGS profile generation
Cohort description
The patient cohort consisted of 273 CRC patients 
(137 males and 136 females) with complete metadata; 
100 patients had been diagnosed with RC, while 173 were 
diagnosed with CC. Patients with CC present different 
laterality of their tumours, 101 and 72 patients had left- 
or right-side tumours, respectively. Further details on the 
composition of the cohort are included in Table 1 and 
Supplementary Figure 1. 
Our 273 patients were classified according to their 
disease stage. We found 22, 112, 106 and 33 in stage I, 
II, III and IV at time of operation, respectively. 217 had 
information on the time between surgery and eventual 
progression. The median age at time of operation was 73 
years (69.5 for RC and 74 for CC). 
NGS data processing
Raw variant calling on 273 colorectal tumour 
samples resulted in a total of 152,520 variant positions, 
where at least one read covered an alternative allele. 
As no matched normal samples were available, the 
differentiation between germline and somatic variation 
turned up challenging. To circumvent this limitation, 
somatic variants of biological relevance were identified 
by technical and manual filtering. These cautiously 
applied filters removed known germline variants and those 
variants predicted to have only minor biological impact. 
Technical and biological filters
Applying technical filters (read depth greater or 
equal than 10 and fraction of alternative alleles (AAF) 
in the range between 0.05 and 0.95) reduced the total 
number of variants to 26,973. Of these, 4,454 variants 
were found in at least one of the genomic databases used 
for filtering, as described in Methods. Of the remaining 
22,519 variants, 18,222 were identified as ‘modifier’ or 
‘low impact’ by SnpEff [8].
Manual filtering
Manual inspection of the variant table revealed some 
genes and positions that were clearly overrepresented 
due to a strange biological composition, e.g. TBP 
(6:170561916–17561960) and LURAP1L (9:12775850–
12775885) contain G/S and Q-repeats, respectively, which 
are found in various lengths throughout a population, 
while KRTAP4-5 consists of ~26 pentameric AA-repeats, 
although this number can vary between individuals. 
Moreover, ERICH6B (13:45596547–45596602) was 
masked due to in-frame deletions frequently occurring 
in European populations, albeit not identified in our 
automatic filtering steps. After masking out these four 
specific regions, attention was given to frequently 
occurring polymorphisms in dbSNP [9]. Histograms 
of the distribution of the alternative allele frequency 
for all rs-ids present in 4 or more samples are shown in 
the Supplementary File 2. Rs-ids or genomic positions, 
where the alternative allele frequency distributed evenly 
around 0.5, were considered of germline origin and 
removed from the dataset (100 rs-ids/positions). Also rs-
ids, annotated as ‘Benign’ in ClinVar [10] and not having 
any connotations to cancer, were removed (58 rs-ids) 
and, finally, a subset of 13 rs-ids were removed for other 
reasons (high co-occurrence with other variants or updates 
made to dbSNP). As the extended panel aims at providing 
a general screening set for patients with CRC, rather than 
at explaining the contribution of rare variation, a final 
filtering step removed genes being mutated in fewer than 5 
samples. After the manual filtering process, our ‘extended 
panel’ consisted of 3,841 high impact variants in 266 
genes. These results are summarized in Supplementary 
Figure 3. 
Identification of most recurrently mutated genes
Most frequently mutated genes
Table 2 displays the top 25 most frequently mutated 
genes in the 273 patients with CRC. Interestingly, 151 
(54.9%), 143 (52%), and 73 (26.5%) of the patients 
present at least one somatic mutation in known tumour 
suppressor genes TP53, APC and FAT4, respectively. The 
commonly reported oncogene KRAS is also found in the 
CRC samples. Namely, 76 (27.6%) of the tumours present 
somatic mutations in this gene. 
The fact that SYNE1 appears mutated in 90 (32.7%) 
tumours might be purely artefactual, given the extreme 
length of this gene, encoding for 8797 amino acids. In 
order to correct for the increased probability of finding 
longer genes among the recurrently mutated ones, we 
normalised the mutated counts with respect to the total 
nucleotide count of the genes (Table 3). As expected, 
SYNE1 disappears from the ranking, while known 
cancer-relevant genes such as KRAS, TP53 and APC 
prevail. OR2L13, an olfactory receptor gene, known to 
hypermutate in spite of its commonly assumed neutrality, 
ranks high in the corrected list. Moreover, the variants 
found in this gene are likely germline rather than somatic. 
The hypervariability of the gene makes it difficult for 
filtering approaches to discern this subclass of rapidly 
evolving gene families and to filter germline variation 
satisfactorily. 
Most frequently mutated local regions
Mutations in cancer genes, especially oncogenes, 
tend to group around particular positions of the protein 
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[11]. A sign that these regions retain functional relevance, 
when mutated, confers an adaptive advantage to cancer 
cells, - a proxy for the identification of novel candidate 
driver genes. To isolate regions of the genes that 
accumulate mutations, we characterised the mutation 
burden per exon as a proxy for functional unit (Table 4). 
The last exon (exon 16) of APC is the one accumulating 
the most mutations, as 120 patients carry a mutation in 
this exon. Followed by exon 2 in KRAS (n = 63) and exon 
8 in TP53 (n = 47). These are known cancer-related genes 
previously discussed. A runner-up in this classification 
is the first exon of the protocadherin gamma subfamily 
A 8 gene, PCDHGA8, which appears mutated in 44 of 
our CRC patients. This gene has not been previously 
associated to CRC. 
Furthermore, we explored, whether mutations were 
distributed across the entire exon or targeted a limited 
number of preferred amino acids. The latter would help 
relate the pernicious effect with a functional role for the 
affected amino acid. Several positions stand out in this 
analysis (Table 5). Examples are position 12 of KRAS 
(n = 47), mutation of amino acid 600 in BRAF (n = 29), 
or the accumulation of somatic mutations in position 273 
of TP53 (n = 20). Interesting from this analysis is the 
incorporation of a frequently mutated (n = 25) position 650 
in the AXIN1 gene. This gene is a regulator of apoptosis 
via induction of the WNT pathway, and consequently, 
likely driving cancer aetiology in the affected patients. 
Most frequently mutated OncodriveCLUST spatial 
clusters
An extension of the previous approach is the 
consideration of spatial clusters instead of individual 
positions as a proxy for functional hot-spots. 
OncodriveCLUST [12] is a method to identify grouping 
of mutations positively selected during clonal evolution 
of tumours. One main strength of the method is that a 
homogeneous baseline mutation probability across all 
genes is not assumed, as this is likely an oversimplication. 
In contrast, OncodriveCLUST creates a background model, 
using silent mutations, which are supposed to be under no 
positive selection and may reflect the baseline mutability of 
different positions across the gene. OncodriveCLUST was 
run, using default parameters and the results displayed in 
Table 6. The clusters identified vary in length and include 
recurrent individual positions. As expected, the highly 
ranking genes previously identified (KRAS, BRAF, TP53, 
APC, AXIN1, …) also rank high in this method. However, 
it provides a finer grain definition of the hot-spots. This is 
the case of KRAS 12-14, mutated in 62 patients (respect to 
the 47 identified before on position 12). 
Table 1: Description of the cohort after filtering
Filtered retrospective cohort (N = 273) Progression free survival (N = 217)
Cancer type CC RC CC RC
Samples 173 100 136 81
Gender
Male 81 56 65 43
Female 92 44 71 38
Stage
I 10 12 10 6
II 78 34 67 31
III 63 43 55 39
IV 22 11 4 5
Tumour location
Right sided 72 - 56 -
Left sided 101 - 80 -
Post-operative treatment
None 139 94 104 78
Chemotherapy 33 3 32 3
Pre-operative treatment
Radiation therapy 1 3 0 0
Age at time of operation
Median 74 69.5 74 69
Mean 71.5 70.3 71.1 69.2
Oncotarget9047www.impactjournals.com/oncotarget
Correlation to outcome/other metadata 
Regions identified by OncodriveClust, enriched for 
mutations, were included in a Cox regression analysis to 
find genomic areas that are negatively affecting overall 
survival (OS) and/or progression free survival (PFS). 
No mutated genes were found to be significant 
predictors of OS or PFS for RC patients, neither when 
using all genes with mutations for the regression model, 
nor when only looking at genes mutated in at least five 
samples.
The pooled cohort of CC and RC patients reveals 
six regions with consistent non-zero coefficients in the 
Cox regression analysis. Table 7 reports the regions and 
log rank p-values of hazard ratios. Four clusters/positions 
were found to be significant predictors of reduced 
survival time, when reducing covariate space to include 
only clusters identified in cluster analysis. BRAF 600 and 
MPO 332 were found to be mutated in 11.1% (n = 24) 
and 4.6% (n = 10) of CC samples, respectively. Similarly, 
CYP2B 181 (n = 8, 3.7%) and TP53 305:307 (n = 8, 
3.7%). Although several genes and clusters are mutated 
much more frequently than these two, they are not found 
to be significant prognostic markers (Figure 1A and 1B, 
respectively). A total of 47 (21.7%) individual patients 
present mutations in one or more of these regions.
The role of BRAF and TP53 as (proto)oncogenes 
is widely described in the literature. Contrarily, CYP2C8 
(Cytochrome P450 2C8) and MPO (Myeloperoxidase) is 
less established. CYP2C8 is involved in the metabolism of 
several common drugs, and have been related to reduced 
metabolism of paclitaxel in in vitro studies [13], but 
the same effect has not been shown in vivo. Contrarily, 
several polymorphisms in CYP2C8 have previously been 
investigated for potentially protective roles in CRC, but 
with negative results [14].
MPO is a widely used marker for inflammatory 
bowel disease [15], being an enzyme playing a central part 
in the host defense system and a well-known biomarker 
for chronic inflammation of the large intestine. Mutations 
in MPO 332 have previously been reported to increase 
hazard ratio for acute lymphoblastic leukemia patients 
[16], but have not been reported in relation to CRC. 
Position 332 is located in close proximity to a metal 
Table 2: Most frequently mutated genes
Gene Sample count Sample freq (%) COSMIC freq. (%) ICGC freq. (%)
TP53 151 54.9 43.5 57.6
APC 143 52 41.2 58.6
SYNE1 90 32.7 26.9 30.0
KRAS 76 27.6 34.7 35.4
FAT4 73 26.5 19.6 22.4
LRP2 71 25.8 17.5 12.4
LRP1B 61 22.2 20.4 18.6
DNAH5 61 22.2 17.0 18.9
CSMD1 59 21.5 13.3 14.3
ATM 57 20.7 22.7 12.4
DMD 49 17.8 3.5 10.5
PCDHGA8 45 16.4 5.6 24.9
CSMD3 45 16.4 21.2 17.8
RYR2 42 15.3 19.1 20.5
PIK3CA 42 15.3 13.5 19.2
AXIN1 41 14.9 3.3 −
MPO 40 14.5 2.7 −
SLC22A1 39 14.2 1.6 −
ZNF208 38 13.8 5.1 −
BRAF 38 13.8 12.3 10.5
SCN10A 36 13.1 6.2 −
PCDHGB4 36 13.1 4.3 27.3
OR2L13 36 13.1 1.9 7.6
FBXW7 36 13.1 11.4 13.8
CES1 36 13.1 2.3 −
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binding site (positions 334, 336, 338 and 340), and thus 
one might hypothesize that this mutation is changing the 
enzymatic activity of MPO. 
Progression free survival of CC patients in stage 
I-III
Similarly, a PFS analysis was carried out for CC and 
RC patients separately (Table 8). Three positions/regions 
(BRAF 600, MPO 332 and TP53 305:307) were found to 
significantly impact PFS for CC patients, while none were 
found in the RC cohort.
These three genes were also responsible for 
determining the overall survival of colon cancer patients 
in stages I-III as represented in Table 9.
CONCLUSIONS
The future of CRC treatment goes through patient 
stratification and precision treatment, customised to 
the individual genome of the patient’s tumour. Here we 
proposed a novel model for creating a biomarker panel, to 
facilitate decision making in a clinical scenario. Targeted 
sequencing of a defined number of biomarkers remarkably 
alleviates the economic and technological pitfalls of 
analysing a country wide cohort to a point scalable and 
feasible for clinical practice. We suggest guidelines for 
the filtering of germline variants to facilitate analysis in 
alignment with throughput demands of a clinical setting 
and to ensure the often required patient anonymity. We 
propose a detailed protocol for the inclusion of genes into 
the biomarker panel; we integrate information extracted 
from biomedical literature with forefront text mining 
approaches; we analyse pathways to identify candidate 
genes, and we address the common therapeutic targets 
of commonly administered therapies. These systems 
biology approaches complement the information extracted 
directly from dedicated state-of-the-art databases (among 
others: dbSNP, COSMIC, Uniprot), and the largest cancer 
genomics effort to date [7]. After filtering and validation, 
our panel consists of 266 genes. Finally, Cox regression 
models determine the contribution of specific genes in 
the survival of patients with CRC. With this approach, 
known oncogenes recurrently involved in the onset and 
Table 3: Most frequently mutated genes, corrected by gene length
Gene Weighted mutation frequency
KRAS 0.42
TP53 0.41
OR2L13 0.12
APC 0.08
SKC22A1 0.08
CES1 0.07
FBXW7 0.07
SUPT4H1 0.06
B2M 0.06
PCDHGA8 0.06
MP0 0.06
NRAS 0.05
BRAF 0.05
AXIN1 0.05
PIK3CA 0.05
MT1A 0.05
HIST1H4F 0.05
CYP2C8 0.05
SH3BGRL3 0.04
PCDHGB4 0.04
CYP3A5 0.04
CYP2B6 0.04
ZNF208 0.04
NR1H4 0.04
TCF7L2 0.04
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progression of CRC are confirmed, and a new candidate 
oncogene, whose role has been a matter of recent debate, 
CYP2C8, is proposed as an active driver of cancer. 
MATERIALS AND METHODS
Description of cohorts
The retrospective study population consisted 
of 303 patients, who underwent surgical resection of 
histologically verified adenocarcinomas of the colon 
or rectum at the Departments of Surgery, Horsens, 
Kolding and Vejle Hospitals, Denmark, from January 
1999 through December 2000, and from whom archival 
tumour tissue was available. Patients in our cohort 
presented with disease stages ranging from I to IV, 
as displayed in Table 1 and Supplementary  Figure 1. 
After filtering, our cohort consists of 273 patients with 
CRC. 
Patients dying because of either post-operative 
complications or within one month from the operation 
(N = 24) were not included. Similarly, patients receiving 
neoadjuvant therapy prior to the primary intervention 
(N = 4) were excluded from the survival analysis. Reliable 
overall survival (OS) and progression-free survival (PFS) 
information was available for 217 patients with CRC (136 
CC, 81 RC) including 9 stage IV patients (4 CC, 5 RC) at 
the time of surgery.
Pre-treatment examinations included a chest 
x-ray and ultrasound or CT scan of the abdomen. 
Postoperatively, tumours were histologically classified and 
staged according to the pTNM system [17]. Information 
regarding patient characteristics, relapse status and 
survival were based on patient records and registries. The 
study was reported to the Danish Data Protection Agency 
of Southern Denmark (ID#: 2008-58-0035) and approved 
by the Regional Scientific Ethical Committee for Southern 
Denmark, according to Danish law (ID#: S-20150010). 
The Danish Registry of Human Tissue Utilisation allows 
registered Danish citizens to refrain from scientific 
research, and all the studied patients were confirmed not 
to be included in this registry.
Table 4: Most frequently mutated exons
Gene Exon rank Sample count
APC 16/16 120
KRAS 2/6 63
TP53 8/11 47
PCDHGA8 1/4 44
ZNF208 1/4 38
OR2L13 2/2 36
PCDHGB4 1/4 35
TP53 5/11 32
BRAF 15/18 32
PCDHA10 1/4 31
FAT4 9/17 29
FAT4 1/17 29
TP53 7/11 27
TSHZ3 2/2 27
SLC22A1 7/11 26
AXIN1 7/11 26
PCDHGA2 1/4 24
TP53 6/11 23
PCDHA5 1/4 22
PCDHA3 1/4 22
PCDHGA4 1/4 21
PCDH2A2 1/4 21
AMER1 2/2 20
FAT4 17/17 20
PCDHA8 1/4 19
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Tissue specimens and tissue processing
All tumour containing tissue blocks were retrieved 
from the archives at the Department of Clinical Pathology, 
Vejle Hospital, Denmark, where all specimens originally 
had been processed, using standardized procedures for 
diagnostic purposes. In brief, the surgical specimens had 
been routinely fixed in formaldehyde over night, and 
1 through 6 tissue blocks from each tumour had been 
dehydrated and embedded in paraffin. One 4 μm thick, 
hematoxylin-eosin (HE) stained tissue slide was cut 
from each tissue block and reviewed by an experienced 
pathologist for tumour content (i.e., tumour cell nuclei) 
in steps of 10%. Tissue blocks with a tumour nuclear 
fraction, subjectively estimated to be lesser than 30%, 
were excluded from the study, resulting in the inclusion 
of 1 through 3 tissue blocks from each surgical specimen. 
When cutting the tissue sections, care was taken 
to avoid contaminating tumour tissue from one case 
to another. Thus, cleaning of the working area was 
undertaken after cutting each case. Moreover, the 
technician changed gloves, replaced the knife on the 
microtome, and cleaned the microtome after finishing 
cutting the tissue blocks from individual cases. Tissue 
sections were placed in microtubes (MCT-150-C; 
1.5 ml RNase/DNase/pyrogen safe; Axygen, USA), and 
transported to Exiqon A/S for further processing.
Preparation of tumour tissue
In an initial prototype phase, five tumours were 
selected from the cohort to study the practical handling 
of the specimens, such as the DNA extraction as a 
function of the degree of infiltration of inflammatory 
cells in the tumour tissue, and the influence of intra-
tumoural heterogeneity. These issues are of outmost 
concern for the clinical applicability of the laboratory 
technique. Tumours were selected so that each would 
have 4 blocks of tumour tissue available. Two 15 μm 
thick tissue sections were cut from each of the 4 tissue 
blocks available from each case, and placed in separate 
microtubes. Cleaning of the working area, change of 
gloves and microtome knife, as well as cleaning of the 
microtome, were carried out after cutting each block 
Table 5: Most frequently mutated gene positions
Gene Pos (AA) Sample count % samples mutated in gene
KRAS 12 47 61.8
BRAF 600 29 76.3
AXIN1 650 25 61.0
OR2L13 265 24 66.7
TP53 273 20 13.2
PCDHGA8 770 18 40.0
SLC22A1 425 15 38.5
MPO 332 15 37.5
TP53 175 15 9.9
PCDHGB4 420 14 38.9
KRAS 13 14 18.4
PCDHA10 81 13 39.4
PIK3CA 1047 11 26.2
APC 876 11 7.7
PMS2 597 11 42.3
CES1 285 10 27.8
TP53 248 10 6.6
CYP2C8 181 10 47.6
FAT4 4726 9 12.3
GGT1 372 9 50.0
TP53 282 9 6.0
TOP1 81 9 64.3
SLC22A1 420 8 20.5
CES1 144 8 22.2
FCGR3B 114 8 80.0
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from individual cases. Moreover, two additional 15 μm 
thick tissue sections were cut from each of the same 
tissue blocks, and mutually placed in one microtube 
per case (Supplementary Table 1). All sections were cut 
adjacently, with one additional HE-stained section at the 
top and the bottom of the tissue section stack, to ensure 
the content of tumour tissue. On these two latter tissue 
sections, the content of inflammatory cells was estimated 
semi-quantitatively by an experienced pathologist (score: 
low or high). Also, the tumour cell fraction (i.e., the 
tumour nuclear fraction) was estimated subjectively in 
the same session, as mentioned above.
Table 6: Most frequently mutated gene intervals, as defined by OncodriveClust
Gene Interval Sample count % of samples mutated in gene
KRAS 12–14 62 81.6
BRAF 600 29 76.3
TP53 266–277 27 17.9
TP53 235–251 25 16.6
AXIN1 650 25 61.0
TP53 161–180 24 15.9
SLC22A1 419–425 24 61.5
OR2L13 265 24 66.7
PCDHGA8 770 18 40.0
APC 1303–1322 16 11.2
MPO 332 15 37.5
PIK3CA 542–549 14 33.3
PCDHGB4 420 14 38.9
PCDHA10 81 13 39.4
PMS2 595–597 12 46.2
TP53 282–296 12 7.9
PIK3CA 1043–1047 12 28.6
APC 876 11 7.7
APC 213–216 11 7.7
TP53 190–197 11 7.3
PCBP1 100–102 10 100.00
CYP2C8 181 10 47.6
CES1 285 10 27.8
TOP1 80–81 10 71.4
APC 1404–1415 9 6.3
Table 7: Intervals with non-zero coefficients in Cox-regression on pooled cohort
Overall survival Progression free survival
Stage I-III I-IV I-III I-IV
Gene Interval p-value HR p-value HR p-value HR p-value HR
BRAF 600:600 9.5e-3 2.0 1.2e-3* 2.0 4.6e-3* 2.1 1.2e-3* 2.2
CYP2C8 181:181 6.0e-3* 2.6 1.4e-2 2.3 5.0e-3* 2.7 9.2e-3 2.5
MPO 332:332 8.4e-4* 2.9 6.5e-4* 2.6 4.7e-3* 2.6 8.4e-3 2.4
NR1H4 183:189 8.2e-2 2.0 3.0e-2 2.2 4.4e-2 2.3 2.7e-2 2.5
TP53 235:251 9.5e-2 1.66 1.2e-1 1.54 6.6e-2 1.74 5.1e-2 1.76
TP53 305:307 2.6e-3* 3.1 5.3e-3* 2.7 3.5e-3* 3.0 1.1e-3* 3.1
OS and PFS are reported as independent analyses. 4 regions are predicted to have a significant negative impact on PFS after 
Bonferroni correction for multiple testing. [Significant Bonferroni corrected p-value: 8.3e-3 (n = 6)].
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Figure 1: Overlap between the minor allele frequency (MAF) databases dbSNP, ExAC and GenomeDK used in the 
project.
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A subsequent phase considered the remaining 
tumours. Tissue availability imposed some restrictions. 
For example, when screening HE-stained sections from 
the individual tumours of all 273 patients, the threshold 
of 30% tumour content had diminished the number of 
formalin-fixed, paraffin-embedded (FFPE) tissue blocks 
to 1 through 3 for each case. Within these tissue blocks 
it was, however, evident that some cases had rather low 
tumour content. Thus, the individual cases were divided 
into tumours of low (N = 30) and high fraction (N = 243) 
of malignant tumour cells.
Cutting tissue sections from these FFPE tissue 
blocks for the discovery study was modified according 
to the knowledge obtained in the prototype phase. Thus, 
the efficiency of the enzymatic digestion of the tissue 
slides was improved by using 10 μm thick tissue sections. 
Moreover, the intra-tumoural heterogeneity did not 
profoundly influence the results obtained (Supplementary 
Figure 2). Accordingly, a total of six 10 μm thick tissue 
sections were cut from each FFPE tissue block; i.e., in the 
case of only one FFPE tissue block per patient, all sections 
were cut from this block, whereas in the case of 2 or 3 
FFPE tissue blocks per patient, 3 or 2 tissue sections were 
cut from the individual tissue blocks, respectively. All 6 
tissue sections from each patient were mutually placed in 
microtubes, using the working setting stated above. For 
quality control, one 4 μm thick, HE-stained tissue section 
was cut from each FFPE tissue block, after cutting the 
adjacent sections, mentioned above, to ensure the tumour 
content (≤30% or >30% adenocarcinoma cell nuclear 
fraction) of the individual cases. 
Construction of the target gene list
Selection of frequently mutated genes
To identify relevant gene targets for sequencing, 
we selected a panel of gene candidates based on literature 
reviews and publicly available databases (Supplementary 
Table 3). All gene names were mapped HGNC identifiers, 
using the R package HGNChelper before merging into a 
combined gene matrix. A total of 1426 unique genes were 
scored based on nine features (Supplementary Table 4) 
encompassing information about their mutation frequency 
Table 8: Intervals with non-zero coefficients in Cox-regression on colon cancer and rectal cancer patients, respectively
Progression free survival
Location Colon cancer Rectal cancer
Stage I-III I-IV I-III I-IV
Gene Interval p-value HR p-value HR p-value HR p-value HR
BRAF 600:600 6.4e-5* 3.0 3.3e-5* 2.9 0.2 0 0.56 0.56
CYP2C8 181:181 3.7e-2 2.5 4.7e-2 2.44 7.7e-2 2.87 0.11 2.54
MPO 332:332 2.3e-3* 3.8 3.8e-3* 3.6 0.23 1.87 0.29 1.73
NR1H4 183:189 4.8e-2 3.05 6.2e-2 2.9 0.33 1.78 0.13 2.16
TP53 235:251 0.28 1.57 0.34 1.5 0.12 1.96 0.078 2.05
TP53 305:307 2.8e-3* 3.7 4.2e-4* 4.1 0.39 1.85 0.45 1.71
APC 1303:1322 8.1e-2 2.1 0.11 1.97 0.37 1.6 0.48 1.44
Three positions/intervals which were also identified in the pooled analysis are significant after Bonferroni correction for 
multiple testing [Significant Bonferroni corrected p-value: 7.14e-3 (n = 7)].
Table 9: Intervals with non-zero coefficients in Cox-regression on colon
Overall survival
Location Colon cancer
Stage I-III
Gene Interval p-value HR
BRAF 600:600 9.1e-6* 2.8
CYP2C8 181:181 0.13 1.99
MPO 332:332 1.0e-3* 3.2
TP53 305:307 0.22 0.5
PCDHBG4 420:420 3.7e-3* 3.2
Three positions/intervals are significant after Bonferroni correction for multiple testing [Significant Bonferroni corrected 
p-value: 0.01 (n = 5)].
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and known association with CRC. The score was computed 
for each gene by summing the number of occurrences of 
the gene across all nine features. Genes were then ranked 
based on their score (ties were resolved by selecting the 
highest CRC mutation frequency as listed by COSMIC). 
As there is overlap among the selection criteria defined in 
Supplementary Table 4, the scoring algorithm resulted in 
93 genes with a positive score (score ≥0). Six additional 
genes with a mutation frequency greater than 7% were 
added to the gene panel, giving a total of 99 gene targets.
Extension of gene panel
In a subsequent step, the aforementioned set of 
genes was extended to include additional genes in which 
mutations likely play a significant role in the aetiology 
of CRC. Several gene lists were constructed, including: 
a) Genes found to be co-mentioned with CRC in 
PubMed abstracts, b) genes from selected pathways, c) 
genes with proteins targeted by compounds in relevant 
oncologic treatments, d) genes that are often mutated in 
CRC according to our analysis of data from The Cancer 
Genome Atlas (TCGA) [7], and e) genes that were hand-
picked based on expert knowledge. The content of these 
lists will be disclosed in the following sections. 
Genes from text mining
Using Intomics’ database of synonyms for 
diseases and genes, we text mined a corpus consisting of 
13,417,371 abstracts from PubMed dating from before 
September 2013. A total of 53,930 abstracts mentioned 
CRC or one of its synonyms, and for each gene a Fisher’s 
exact test assessed, whether synonyms for the gene were 
mentioned together with synonyms for CRC more often 
than would be expected by random. After adjustment for 
multiple testing at a Bonferroni-corrected significance 
of 5·10–7, 375 genes significantly associated with CRC, 
according to the text mining.
Genes from pathways
A list was constructed consisting of genes from the 
KEGG pathways [18] “hsa05210” (CRC), “hsa04370” 
Figure 2: Filtering of variants by database (Danish reference genome, dbSNP and ExAC). Overlap of filtered variants 
between databases. DK-ref: Variants found in >= 5% of parents from panel behind Danish reference genome. 1KG: Variants found in >= 
5% of a population in 1000 Genomes Project. ExAC: Variants found in >= 5% of ExAC cohort globally or European subset.
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(VEGF signalling pathway), and genes with proteins 
annotated in UniProt [19] with GO-accession [20] 
“GO:0048010” (VEGF receptor signaling pathway) 
or descending accessions. This list was then filtered as 
described below.
Genes as targets related to therapy
Protein targets for the compounds bevacizumab, 
capecitabine, cetuximab, fluorouracil (5-FU), irinotecan, 
oxaliplatin and panitumumab, all of which are used in 
treatment of CRC, were extracted from DrugBank [21], 
and the corresponding genes were added to a list. In 
addition, genes corresponding to protein targets for the 
above compounds and floxuridine, regorafenib, sorafinib, 
sunitinib and vatalanib, also used in therapy of CRC, were 
extracted from the CHEMBL database [22], filtered for 
biological relevance as described below, and added to the 
list.
Genes from TCGA data
Data for somatic mutations in patients with 
adenocarcinoma of the colon or rectum were downloaded 
from The Cancer Genome Atlas [7] in December 2013. 
Low impact mutations according to SNPeff [8] were 
discarded, and for each gene the number of remaining 
mutations was normalised taking gene length into 
consideration. The 50 genes with the highest mutation rate 
were then used for further analysis.
Hand-picked genes
EGFR, EPCAM, MLH3 and PMS2 are human genes 
where the corresponding proteins are annotated with the 
“Hereditary non-polyposis CRC” keyword in UniProt 
[19]. These were added to the panel. 
Filter of biologically relevant genes
The different gene lists discussed above were 
filtered according to their biological relevance before they 
were included in the panel. 
The protein-protein interaction network InBio 
MapTM developed by Intomics [23] was used to identify 
genes, whose proteins interact with the proteins coded by 
the 50 genes that had the highest mutation rates in the data 
from TCGA. The rationale behind the filtering is that if a 
mutation in gene A is relevant, then mutations in gene B 
may also be relevant, given that both their protein products 
are part of the same protein complex. A gene was included 
on this list if it was one of the 50 genes with the highest 
mutation rates, or if at least 10% of its corresponding 
protein’s known interactors were among the proteins 
Figure 3: Survival plots of patients with mutations in the BRAF and MPO genes. (A) Survival-plot of patients with mutation 
(red, n = 14) or reference (black, n = 81) in BRAF 600. Hazard ratio = 3 (1.6–5.7). (B) Survival-plot of patients with mutation (red, n = 5) 
or reference (black, n = 90) in MPO 332. Hazard ratio = 3.1 (1.2–7.9).
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coded by these 50 genes (only high-confidence interactors 
were considered).
Construction of genomic libraries
DNA isolation
DNA was isolated from six 10 µm slices of 
formalin-fixed, paraffin-embedded (FFPE) tissues using 
the QIAamp DNA FFPE Tissue kit (Qiagen Inc.) with the 
following amendments: Samples were deparaffinised four 
times with 1 mL xylene (Sigma Inc.). Digestion steps were 
performed in double volumes, in that protease K digestion 
was performed in 360 µL ATL buffer, using 40 µL 
Protease K overnight at 65° C, followed by a heating step 
of 75° C for 15 min. RNA digestion was carried out, using 
4 µL RNase A, then 400 µL AL buffer was added and 
400 µL ethanol (100%), vortexed and loaded into columns 
in two steps. DNA was eluted in 75 µL nuclease-free water 
and quantified using a Nanodrop 1000 spectrophotometer 
(Thermo Scientific). 
Fractionation
Samples were fractionated, using M220 Focused-
Ultrasonicator (Covaris Inc.), aiming at average size of 
200 bp. An aliquot of 3 µg of genomic DNA was diluted to 
a final volume of 130 µL and transferred to a microTUBE 
AFA Fiber Snap-Cap tube, using the following settings 
at 4° C: Peak incident power 50, duty factor 20%, cycles 
per burst 200, treatment time 300 seconds. Samples were 
purified and concentrated, using AMPureXP magnetic 
bead system (1.8x volume beads), washed twice in 70% 
ethanol (Agencourt Bioscience Corporation), and eluted in 
nuclease-free water. The quality of the fractionation was 
checked on a bioanalyzer, using DNA High Sensitivity 
chips.
Genomic library construction
Library construction and target gene enrichment 
were performed using the SureSelect XT Target 
Enrichment system (Agilent technologies Inc.), according 
to the manufacturer’s instructions based on a published 
protocol [24]. In short, the fractionated genomic DNA 
(3 µg) was end-repaired, 3ʹ dA overhangs added followed 
by adapter ligation. Between the three library generation 
steps, the samples were purified and concentrated, using 
AMPureXP bead system (1.8x volume beads), washed 
twice in 70% ethanol (Agencourt Bioscience Corporation) 
and eluted in nuclease-free water. The libraries were 
finally amplified (12 cycle protocol), using Hercules II 
fusion PCR system (Agilent Inc.) and purified again with 
AMPureXP bead system. Libraries were quantified, using 
Nanodrop 1000 (Thermo Fisher Inc.).
Targeted sequencing
Biotinylated RNA baits
In the initial pilot phase, commercially available 
SureSelect XT Human-All-Exome RNA baits (Agilent 
Technologies Inc.) were used following the instruction 
from the manufacturer. 
The retrospective cohort was interrogated, using 
a novel panel of 266 genes. These genes were uploaded 
into the Agilent SureSelect E-array software to design 
56,008 probes (3× tiling density), using moderately 
stringent masking. The probes covered exons (± 10 nt.), 
3ʹ UTRs and 5ʹ UTRs of the 266 candidate genes under 
investigation. Total genomic region spanned 1.357 
Mbp. The sequences of all 56,008 baits are listed in the 
Supplementary File 1. Biotinylated RNA baits were 
synthesised by Agilent Inc. for the SureSelect XT Target 
Enrichment system. 
Pooling and hybrid capture
DNA libraries (750 ng) were transferred to 
1.5-mL polypropylene sample tubes, lyophilized with 
a speedvac evaporator, and resuspended in 3.5 μL of 
nuclease-free water. Solution-based hybrid capture was 
performed according to the SureSelect XT protocol with 
overnight hybridization at 65° C, standard washing and 
Dynabead purification (Thermo Fisher Inc.) according 
to the manufacturer’s instructions. Libraries were 
amplified (12 cycle protocol) with Hercules II Fusion 
PCR system and SureSelect 96 index system, using half 
of the enriched library (bound to Dynabeads) and quality 
checked on Bioanalyzer DNA High Sensitivity chip 
(Agilent Technologies Inc.). Then libraries were diluted 
to 1:40,000 and quantified by KAPA qPCR system for 
Illumina libraries (KAPA biosystems Inc.), using library 
standards according to manufacturer’s instructions on a 
LightCycler 480 qPCR system (Roche), and the second 
derivative MAX Cq calculation method. Libraries were 
run on a HiSeq 2500 sequencer (Illumina Inc.), using 
version 3 chemistry and a 75 bp paired end protocol. 
After sequencing, BCL data files were de-multiplexed 
and converted into FASTQ data, using bcl2fastq software 
(Illumina Inc.). 
Heterogeneity analysis on prototype phase 
samples
Inter- and intra-sample heterogeneity of the 5 
samples from the prototype phase was assessed by 
comparing the mutation profile between samples from 
different tumours and slices from the same tumour.
For each slice, the overall sequencing quality was 
assessed using fastqc v0.11.2. Sequences were trimmed 
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and adapters and low quality sequences were removed 
using cutadapt v.1.2.1 and prinseq-lite v0.20.4 to improve 
mapping to the human reference genome.
Reads were mapped to the hg19-build of human 
reference to ensure compatibility with BED-regions 
provided for WXS. A common artefact, when sequencing 
FFPE samples, is a high proportion of duplicate reads. 
Those were marked and removed before further processing 
using Picard-tools - MarkDuplicates v1.109.
The resulting files from the mapping were subset to 
contain only reads mapping to gene regions specified in 
Agilent SureSelect WXS kit with samtools v0.1.18.
After preprocessing of the samples, a thorough 
analysis was carried out to identify mutations in a range 
of genes and to investigate both inter- and intra-sample 
heterogeneity based on the mutation profiles of the 
specimens. Thus, single nucleotide polymorphisms (SNP) 
and indels were called with VarScan v2.3.7. Identified 
SNPs and indels were filtered with dbSNP138 [17] and 
annotated with Annovar v2.0. 
Variant calling on discovery cohort
To assess the intra- and inter-sample heterogeneity 
the overlap between individual slices and samples was 
analysed with Varscan v2.3.7 and custom made scripts.
Sequencing read quality was assessed with fastQC 
v.0.11.2. To ensure high reads quality before mapping, low 
quality reads were removed, and adapter and low quality 
bases clipped from 3ʹ and 5ʹ using cutadapt v.1.8.1 and 
prinseq-lite.pl v.0.20.4.
Reads were mapped to GRCh38, using bwa mem 
v.07.12 [25]. Duplicate reads were marked (Picard-tools 
1.128) [26], and only reads mapping in proper pairs were 
selected for variant calling.
Variant calling was performed with bcftools v.1.2, 
utilizing the multi-allelic caller to ensure conservation of 
information on multi-allelic sites. Indels were left-aligned, 
and multi-allelic sites were split into bi-allelic records, 
which were then annotated with information from dbSNP 
and the Danish Reference Genome [27, 28]. Variant effects 
were evaluated for canonical transcripts with snpEff v.4.1l 
[8], using genome version GRCh38.76.
Several criteria were used to identify somatic 
variants of biological relevance. Allele frequencies were 
defined as the number of high quality bases supporting 
the allele divided by the total number of high quality 
bases. We used the same definition of “high quality” as in 
the samtools software package [29]. In each sample, the 
variant positions were flagged according to these criteria:
• If the QUAL column in the VCF file is below 20, 
the “LQ” (low quality) flag is used.
• If the number of high quality bases per genomic 
position is below 10, the “LD” (low depth) flag 
is used.
• If one alternative allele frequency is more than 
95%, or if the number of high quality non-
alternative alleles is below 5, the “HF” (high 
frequency) flag is used, if 5 or more high quality 
reads support the alternative allele. Since the 
tumour contents of the samples are expected to 
be much lower than 95%, somatic mutations will 
not have alternative allele frequencies that are so 
high.
• If all alternative allele frequencies at the position 
are below 5% or supported by less than 5 high 
quality bases, the “LF” (low frequency) flag is 
used. Somatic mutations that are driver mutations 
will not have such low allele frequencies, unless 
the tumour content of the sample is very low.
• If at least one alternative allele has a frequency of 
at 5% or more and is supported by 5 or more high 
quality reads, the “G5”, “DK”, “EG”, and “EE” 
flags are used, if, respectively, all such alleles 
have been observed in at least 5% of
 ◦ a population in the 1000 Genomes Project 
[30] (the same as in the dbSNP database [9]),
 ◦ the population in the Danish Reference 
Genome project [27, 28],
 ◦ the population in the Exome Aggregation 
Consortium [31], and the European sub-
population in the Exome Aggregation 
Consortium.
• If at least one alternative allele has a frequency 
of 5% or more and is supported by five or more 
high quality reads, and all such alleles have 
been observed either in at least 5% of any of 
the aforementioned populations, the “CO” flag 
(common) is used. Note the “CO” flag can be 
set for a position, even though none of the “G5”, 
“DK”, “EG”, or “EE” flags are set, if several 
alternative alleles are seen at the position, and one 
allele has one of the flags and another allele has 
another of the flags.
• Each alternative allele’s biological impact 
on canonical transcripts was assessed using 
the snpEff software package. The software 
assesses the level of impact, using the categories 
“modifier”, “low”, “moderate”, and “high”. The 
maximum impact level for the alternative alleles 
with frequencies of 5% or more, and supported by 
5 or more high quality reads, was computed and 
represented by the flags “I0”, “I1”, “I2”, and “I3” 
corresponding to the four impact levels.
The overlap between the different databases is 
represented in Figure 2, whereas the distribution of variants 
in each category is represented in Figure 3. Supplementary 
Table 2 summarises the distribution of flags across the full 
set of variants. Note that not all combinations are possible 
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(e.g. “G5” implies “CO”), and that the same variant will 
count multiple times if observed in multiple samples.
Cox regression 
To identify regions with predictive power regarding 
survival, a proportional hazards model (Cox regression) 
was applied to all regions identified with OncodriveClust. 
OncodriveClust identified 378 mutational hot-spots that 
will be referred hereafter as clusters. Given that the 
number of covariates (i.e. 378 clusters) is high, compared 
to the number of patients (n = 217), we used a LASSO-
model, which will select one of a group of correlated 
predictors and shrink the rest to zero [32]. 
Cox regression survival analyses were carried out 
for the following groups:
1) OS for pooled group of cancer patients in stage I-IV
2)  OS for pooled group of cancer patients in stage 
I-III
3)  PFS for pooled group of cancer patients in stage 
I-IV
4)  PFS for pooled group of cancer patients in stage 
I-III
5) PFS for CC patients in stage I-IV
6) PFS for CC patients in stage I-III
7) PFS for RC patients in stage I-IV
8) PFS for RC patients in stage I-III
As only 9 patients were in stage IV at time of 
operation, the differences in PFS with and without this 
group were minimal. Regions mutated in more than five 
samples were used as covariates for model selection.
Cox-regression analysis was performed with the 
glmnet R-package, which is an elastic net LASSO fit. The 
model uses an elastic net to bridge the gap between ridge 
regression (shrinking correlated predictors towards each 
other) and LASSO (discard non-influential coefficients). In 
the model, the parameter a is used to control the elastic net 
between a complete ridge model (α = 0) and a complete 
LASSO model (α = 1). Using varying degrees of a to favor 
either a ridge model or a LASSO model provided the same 
results, with only size of coefficients varying between the 
models.
Calculating standard error for non-zero coefficients 
is not meaningful for biased estimation methods such 
as LASSO, since this procedure aims at reducing the 
variance of estimators. Thus, to evaluate the significance 
of predictors carrying non-zero coefficients, these 
parameters are tested in a regular survival analysis to 
calculate statistical significance and hazard ratios.
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